CELLphenomics specializes in the development and cultivation of patient-derived 3D cell culture models (PD3D®) from solid tumor tissues, enabling high-throughput efficacy testing and personalized toxicity profiling for drug discovery. Their extensive biobank of over 600 complex in vitro models, combined with clinical and molecular data, provides researchers with biologically relevant tools to assess treatment sensitivity and resistance in cancer therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery and preclinical development rely on models that accurately represent the complexity of solid tumors, but traditional cell culture methods often fail to recapitulate the biological properties of the original tumor tissue. This can lead to inaccurate efficacy testing and toxicity profiling, resulting in costly failures in later stages of drug development.
Solution
CELLphenomics specializes in patient-derived 3D (PD3D®) cell culture models derived from solid tumor tissues, offering a biologically relevant platform for preclinical drug development. Their PD3D® models maintain key histopathological features and genomic makeup of the donor tumor, enabling researchers to study treatment sensitivity and resistance more effectively. The platform facilitates high-throughput efficacy testing, drug combination screening, toxicity profiling, target validation, and biomarker identification, providing a comprehensive solution for assessing cancer therapies.
Target Audience
The primary customers are pharmaceutical companies, biotech firms, and research institutions involved in drug discovery and preclinical development, seeking more predictive and biologically relevant models for cancer research.
Features
- Proprietary PD3D® technology for establishing and cultivating complex 3D cell culture models from patient tumor tissues
- Biobank of over 600 in vitro models from more than 20 tumor entities, complemented by clinical and molecular data
- Models that recapitulate key histopathological features and genomic makeup of the donor tumor tissue
- High-throughput efficacy testing, drug combination screening, and personalized toxicity profiling
- Services for target validation, drug sensitivity correlation with clinical response, and biomarker identification
- Consulting services to guide preclinical development, from experiment design to intellectual property creation
- Genomics and proteomics services through certified partners for comprehensive tumor characterization
- Optim.AI™ for combining small data AI with PD3D® models to enhance research insights